|
FOR US RESIDENTS ONLY
|
Q-RT-PCR Testing & Ph+ CML
Emerging evidence suggests that, in conjunction with achieving a hematologic response and a cytogenetic response, achieving a molecular response to therapy may correlate with improved progression-free survival in patients with Ph+ CML.1
Quantitative reverse-transcriptase polymerase chain reaction (Q-RT-PCR) is the best way to assess molecular response in patients with Ph+ CML.2 Q-RT-PCR enables extremely low levels of Bcr-Abl RNA transcripts to be monitored over time.2
Timely access to consistent and easily interpretable Q-RT-PCR results is important for:
- Assessing whether a patient with Ph+ CML has achieved or is trending toward a desired response to therapy2
- Helping to ensure that a patient’s treatment is optimized over time2
A group of international experts in Ph+ CML is currently working to establish a uniform standard for performing Q-RT-PCR and reporting and interpreting the results.2 These experts recommend that Q-RT-PCR be performed at least every 3 months to assess response to therapy.2
Look for more information on standardized PCR testing offered through CML Alliance™.
- Druker BJ et al. N Engl J Med. In press.
- Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. [p 28]
Testing services offered through CML Alliance ™ partners
Use of this website is governed by the
Terms of Use
and
Privacy Statement
.
Copyright 2008 Novartis Pharmaceuticals Corporation. All Rights Reserved.
|